AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA' GRANDA - Italy 

Ranking results:

Past rankings:

2015
Criterium:Position:
Overall Score:> 1000
Networking Rank (Reputation):> 1000
2011
Criterium:Position:
Overall Score:> 1000
Networking Rank (Reputation):> 1000

Ranking timeline:

Project Participation Performance(2011-01-01 - 2024-12-31 ):

Total Project Funding:

Total funding allocated to projects this organisation participated or coordinated

Funding per Partner:

Since 2014 individual funding per partner. If data is not available at CORDIS: total funding / No of participants.

Projects:

Leadership:

Total number of projects: 5
As coordinator: 0
As participant: 5
Sole participant: 0
Coordinator / Participant Ratio: 0*

*Ratio includes only projects with > 2 partners

Summary:

Total project funding [€]:Projects [No]:
Year:coordinator*participant*per partner  as coordinatoras participant
2015 0 14.829.054 79.750 2
2011 0 12.800.300 314.800 3
*n.b.: These numbers represent the total amount of funds allocated to projects this institution has participated in, not the funding allocated to this institution

Networking:

Partners:

Institution:Projects [No]:
AGENDIA NV2
FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALLHEBRON2
KATHOLIEKE UNIVERSITEIT LEUVEN2
STICHTING HET NEDERLANDS KANKER INSTITUUTANTONI VAN LEEUWENHOEK ZIEKENHUIS2
UNIVERSITA DEGLI STUDI DI TORINO2
ABIEL SOCIETA A RESPONSABILITA LIMITATA1
ALIMENTOS FUNCIONALES Y DE ORIGEN TRADICIONAL SL1
ARTTIC IN BRUSSELS SPRL1
AZIENDA OSPEDALIERA SAN PAOLO1
BOSTON SCIENTIFIC LIMITED1
CENTRO DE INVESTIGACION BIOMEDICA EN RED1
CF CONSULTING FINANZIAMENTI UNIONE EUROPEA1
CONSIGLIO NAZIONALE DELLE RICERCHE1
CONTIPRO PHARMA AS1
DE KORTE WEG BV1
DEUTSCHES FORSCHUNGSZENTRUM FUER KUENSTLICHE INTELLIGENZ1
DOMINAE TRADING1
DUBLIN CITY UNIVERSITY1
EBERHARD KARLS UNIVERSITAET TUEBINGEN1
EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL1
EXPLORA1
FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO1
FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA1
FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA1
FORCE DIMENSION SARL1
FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE1
FUNDACION PARA LA INVESTIGACION DEL HOSPITAL CLINICO DE LA COMUNITAT VALENCIANA FUNDACION INCLIVA1
HELSINKI UNIVERSITY CENTRAL HOSPITAL1
HORIZON DISCOVERY LIMITED1
HPF NUTRACEUTICS1
IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE1
INNOCORE TECHNOLOGIES BV1
INNOVA1
INSTITUT CATALA D'ONCOLOGIA1
KARLSRUHER INSTITUT FUER TECHNOLOGIE1
KUKA LABORATORIES1
KUKA ROBOTER1
L'AZIENDA SOCIO SANITARIA TERRITORIALE GRANDE OSPEDALE METROPOLITANO NIGUARDA1
MEATLESS BV1
MEDIMATON LIMITED1
NATURAL CRUNCH SL1
POLITECNICO DI MILANO1
RENISHAW1
RIJKSUNIVERSITEIT GRONINGEN1
ROYAL COLLEGE OF SURGEONS IN IRELAND1
SIRAFOOD1
SWISS INSTITUTE OF BIOINFORMATICS1
TECHNION ISRAEL INSTITUTE OF TECHNOLOGY1
TECHNISCHE UNIVERSITAET MUENCHEN1
TERRENA SOCIETE COOPERATIVE AGRICOLE1
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD1
THE FOUNDATION FOR MEDICAL RESEARCH INFRASTRUCTURAL DEVELOPMENT AND HEALTH SERVICES NEXT TO THE MEDICAL CENTER TEL AVIV1
THE UNIVERSITY OF LIVERPOOL1
UNIVERSITA DEGLI STUDI DELLA CAMPANIA LUIGI VANVITELLI1
UNIVERSITA DEGLI STUDI DI MILANO1
UNIVERSITEIT UTRECHT1
UNIVERSITY COLLEGE DUBLIN NATIONAL UNIVERSITY OF IRELAND DUBLIN1

Constancy:

Total number of partners: 62
Partner loyalty:
Frequent Partner: (> 2 projects): 0
Rare Partner: 62
Frequent / Rare Partner Ratio: 0

Project overview:

Start dateProjectacronymrolefundingpartners
2015-10-01Molecularly guided trials with specific treatment strategies in patients with advanced newly molecular defined subtypes of colorectal cancer (MoTriColor) MoTriColorparticipant5.996.99211
2015-06-01Diabetes Reversing Implants with enhanced Viability and long-term Efficacy DRIVEparticipant8.832.06214
2011-10-01Innovative functional foods based on sweet lupin protein for cardiovascular prevention LUPICARPparticipant1.023.00012
2011-04-01Active Constraints Technologies for Ill-defined or Volatile Environments ACTIVEparticipant5.778.00019
2011-01-01Modelling and predicting sensitivity to targeted therapies in colorectal cancers COLTHERESparticipant5.999.30011